Page 36 - 南京医科大学自然版
P. 36

第44卷第10期
               ·1352 ·                           南 京    医 科 大 学 学         报                        2024年10月


                   lular carcinoma［J］. J Hepatocell Carcinoma，2024，11：  safety of tirzepatide monotherapy compared with dulaglu⁃
                   581-594                                           tide in Japanese patients with type 2 diabetes（SURPASS J
             ［4］ RAZA S，RAJAK S，UPADHYAY A，et al. Current treat⁃     ⁃mono）：a double⁃blind，multicentre，randomised，phase 3
                   ment paradigms and emerging therapies for NAFLD/  trial［J］. Lancet Diabetes Endocrinol，2022，10（9）：623-633
                   NASH［J］. Front Biosci，2021，26（2）：206-237     ［15］ZHONG H X，DONG J Y，ZHU L Y，et al. Non⁃alcoholic
             ［5］ MARIAM Z，NIAZI S K. Glucagon⁃like peptide agonists：  fatty liver disease：pathogenesis and models［J］. Am J
                   a prospective review［J］. Endocrinol Diabetes Metab，  Transl Res，2024，16（2）：387-399
                   2024，7（1）：e462                               ［16］KLEINER D E，BRUNT E M，VAN NATTA M，et al. De⁃
             ［6］ RIVERA F B，LUMBANG G N O，GAID D R M，et al.          sign and validation of a histological scoring system for
                   Glucagon ⁃ like peptide ⁃ 1 receptor agonists modestly re⁃  nonalcoholic fatty liver disease［J］. Hepatology，2005，41
                   duced blood pressure among patients with and without di⁃  （6）：1313-1321
                   abetes mellitus：a meta⁃analysis and meta⁃regression［J］.  ［17］DIEHL A M，DAY C. Cause，pathogenesis，and treatment
                   Diabetes Obes Metab，2024，26（6）：2209-2228          of nonalcoholic steatohepatitis［J］. N Engl J Med，2017，
             ［7］ LOBKOVICH A，KALE⁃PRADHAN P，LIPARI M. Incre⁃         377（21）：2063-2072
                   tin analogs for weight management in adults without dia⁃  ［18］JUANOLA O，MARTÍNEZ⁃LÓPEZ S，FRANCÉS R，et al.
                   betes［J］. Ann Pharmacother，2024，58（4）：398-406     Non⁃alcoholic fatty liver disease：metabolic，genetic，epi⁃
             ［8］ BARRITT A S，MARSHMAN E，NOUREDDIN M. Review          genetic and environmental risk factors［J］. Int J Environ
                   article：role of glucagon⁃like peptide⁃1 receptor agonists  Res Public Health，2021，18（10）：5227
                   in non ⁃ alcoholic steatohepatitis，obesity and diabetes ⁃  ［19］PETRONI M L，BRODOSI L，BUGIANESI E，et al. Man⁃
                   what hepatologists need to know［J］. Aliment Pharmacol  agement of non ⁃ alcoholic fatty liver disease［J］. BMJ，
                   Ther，2022，55（8）：944-959                           2021，372：m4747
             ［9］ XU L M，WU C F，LIU C M，et al. Therapeutic effect of  ［20］CHALASANI N，YOUNOSSI Z，LAVINE J E，et al. The
                   liraglutide on type 2 diabetic patients with nonalcoholic  diagnosis and management of nonalcoholic fatty liver dis⁃
                   fatty liver disease［J］. Minerva Surg，2023，78（4）：448-450  ease：practice guidance from the American Association
             ［10］EGUCHI Y，KITAJIMA Y，HYOGO H，et al. Pilot study      for the Study of Liver Diseases［J］. Hepatology，2018，67
                   of liraglutide effects in non⁃alcoholic steatohepatitis and  （1）：328-357
                   non⁃alcoholic fatty liver disease with glucose intolerance  ［21］WORM N. Beyond body weight⁃loss：dietary strategies tar⁃
                   in Japanese patients（LEAN⁃J）［J］. Hepatol Res，2015，45  geting intrahepatic fat in NAFLD［J］. Nutrients，2020，12
                  （3）：269-278                                       （5）：1316
             ［11］ARMSTRONG M J，GAUNT P，AITHAL G P，et al. Lira⁃  ［22］BERTUZZI A，CONTE F，MINGRONE G，et al. Insulin
                   glutide safety and efficacy in patients with non⁃alcoholic  signaling in insulin resistance states and cancer：a model⁃
                   steatohepatitis（LEAN）：a multicentre，double⁃blind，ran⁃  ing analysis［J］. PLoS One，2016，11（5）：e0154415
                   domised，placebo ⁃ controlled phase 2 study［J］. Lancet，  ［23］DU Y P，WEI T T. Inputs and outputs of insulin recep⁃
                   2016，387（10019）：679-690                           tor［J］. Protein Cell，2014，5（3）：203-213
             ［12］YAN J H，YAO B，KUANG H Y，et al. Liraglutide，sita⁃  ［24］TITCHENELL P M，LAZAR M A，BIRNBAUM M J. Un⁃
                   gliptin，and insulin glargine added to metformin：the ef⁃  raveling the regulation of hepatic metabolism by insulin［J］.
                   fect on body weight and intrahepatic lipid in patients with  Trends Endocrinol Metab，2017，28（7）：497-505
                   type 2 diabetes mellitus and nonalcoholic fatty liver dis⁃  ［25］DENG A H，WANG Y，HUANG K R，et al. Artichoke（Cy⁃
                   ease［J］. Hepatology，2019，69（6）：2414-2426          nara scolymus L.）water extract alleviates palmitate ⁃ in⁃
             ［13］GUO W，TIAN W J，LIN L，et al. Liraglutide or insulin  duced insulin resistance in HepG2 hepatocytes via the ac⁃
                   glargine treatments improves hepatic fat in obese patients  tivation of IRS1/PI3K/AKT/FoxO1 and GSK⁃3β signaling
                   with type 2 diabetes and nonalcoholic fatty liver disease in  pathway［J］. BMC Complement Med Ther，2023，23（1）：
                   twenty⁃six weeks：a randomized placebo⁃controlled trial［J］.  460
                   Diabetes Res Clin Pract，2020，170：108487                                ［收稿日期］ 2024-04-01
             ［14］INAGAKI N，TAKEUCHI M，OURA T，et al. Efficacy and                              （本文编辑：陈汐敏）
   31   32   33   34   35   36   37   38   39   40   41